SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

202395 citationsJournal Articlehybrid Open Access

Authors

Charles M. Rudin · Memorial Sloan Kettering Cancer Center

Stephen V. Liu · Georgetown University

Ross A. Soo · National University Cancer Institute, Singapore

Shun Lü · Shanghai Jiao Tong University

Min Hee Hong · Severance Hospital

Jong Seok Lee · Seoul National University Bundang Hospital

Maciej Bryl

Abstract

Tiragolumab did not provide additional benefit over atezolizumab and CE in untreated ES-SCLC. The combination was well tolerated with no new safety signals.

Topics & Keywords

Lung Cancer Research Studies Neuroendocrine Tumor Research Advances Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 42, Issue 3, pp. 324-335

DOI: 10.1200/jco.23.01363

Field-Weighted Citation Impact: 21.77